

# TruTrace Technologies Inc.

21:31 25 Jun 2019

## TruTrace Technologies and Shivom team up explore blockchain opportunities in cannabis

TruTrace Technologies Inc (CSE:TTT) (OTCMKTS:TTTSF) announced Tuesday afternoon that it has entered into an agreement with biotechnology data company Shivom Ventures Limited to explore blockchain opportunities in the global cannabis market.

The two companies are teaming via a strategic working relationship to utilize both TruTrace and Shivom's blockchain solutions in the medicinal and cannabis recreational markets.

Shivom is a biotechnology data and analysis company that optimizes the way DNA is shared, secured and evaluated through blockchain and artificial intelligence technology.

READ: TruTrace and Theracann team up to integrate blockchain cannabis quality-control platform with molecular tagging technology  
The agreement marks UK-based Shivom's first step into the cannabis market, according to its CEO Henry Ines, who said in a statement that the company was "excited" to partner with TruTrace.

"As the industry is still in its early stages in terms of understanding and uncovering all of the medicinal benefits associated with the use of CBD, Shivom is keen to work with leading organizations in the space such as TruTrace to further uncover additional therapeutic benefits based on one's genomic profile and unique personal health information," said Ines.

"Shivom has developed some very interesting technology that combines genomics, cryptography and AI, and we are excited to begin collaborating with them," said TruTrace CEO Robert Galarza.

"We plan to explore development and integration opportunities to advance clinical research, and bring greater transparency, insights and viability to the legal medical and recreational cannabis industry."

### Collaboration opportunities

Shivom said that it anticipates there will be numerous opportunities to collaborate with TruTrace to provide clinical research opportunities, medical insights and personalized healthcare products to consumers and patients within the global cannabis ecosystem.

Based in Toronto, TruTrace has developed the first integrated blockchain platform to register and track intellectual property in the cannabis industry, allowing cannabis growers and breeders to identify and secure rights to their intellectual property.


Contact Angela at [angela@proactiveinvestors.com](mailto:angela@proactiveinvestors.com)

Follow her on Twitter @AHarmantas

**Price:** 0.08

**Market Cap:** \$6.42 m

### 1 Year Share Price Graph



December 2018 June 2019 December 20

### Share Information

**Code:** TTT

**Listing:** CSE

**52 week High Low**  
0.495 0.06

**Sector:** Cannabis

**Website:** [trutrace.co](http://trutrace.co)

### Company Synopsis:

*TruTrace is a full-service software company that builds technology to move and track products around the world. With the launch of its premiere product, StrainSecure, TruTrace has developed the first integrated blockchain platform, that registers and tracks cannabis intellectual property from genome to sale.*

[action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

Proactive Investors facilitate the largest global investor network across 4 continents in 4 languages. With a team of analysts, journalists & professional investors Proactive produce independent coverage on 1000's of companies across every sector for private investors, private client brokers, fund managers and international investor communities.

Contact us +44 (0)207 989 0813 [action@proactiveinvestors.com](mailto:action@proactiveinvestors.com)

### No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Content on the Site is provided for information purposes only, and none of the information contained on the Site constitutes an offer, solicitation or recommendation to buy or sell a security. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume which any Content on the Site may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value, suitability or profitability of any particular security, portfolio of securities, transaction, investment, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including Company-related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

The Site does not, and is not intended to, provide investment, tax, accounting, legal or insurance advice, and is not and should not be construed as providing any of the foregoing. You should consult an attorney or other relevant professional regarding your specific legal, tax, investment or other needs as tailored to your specific situation.

In exchange for publishing services rendered by the Company on behalf of Trutrace Technologies Inc. named herein, including the promotion by the Company of Trutrace Technologies Inc. in any Content on the Site, the Company receives from said issuer annual aggregate cash compensation in the amount up to Twenty Five Thousand dollars (\$25,000).